Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi

An antifungal and drug technology, applied in antifungal agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problems of digestive tract irritation, strong accumulation of toxicity, etc. active effect

Inactive Publication Date: 2013-12-25
NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The spread of pathogenic bacteria and the enhancement of drug resistance seriously threaten human health and life. Antibacterial drugs have been widely used as routine drugs in the treatment of AIDS, organ transplantation and chronic wasting diseases (such as cancer, diabetes, uremia, etc.) Treatment, although antibacterial agents currently used clinically (such as ketoconazole, amikacin, gentamicin, vigorconazole, itraconazole, terbinafine, amphotericin, fluconazole, etc.) The curative effect on skin and superficial infection is good, but these antibacterial drugs have strong cumulative toxicity, often causing liver and kidney damage, gastrointestinal irritation, dizziness, allergies, etc. one of the hotspots

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi
  • Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi
  • Application of Lycojaponicumin B in preparation of medicines for resisting human body fungi

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1: Preparation of Sarcaboside B tablets, the compound involved in the present invention:

[0014] Take 20 grams of the compound Sarcaboside B, add 180 grams of conventional excipients for preparing tablets, mix them, and prepare 1,000 tablets with a conventional tablet press.

Embodiment 2

[0015] Example 2: Preparation of Sarcaboside B capsules of the compound involved in the present invention:

[0016] Take 20 grams of the compound Sarcaboside B, add 180 grams of conventional auxiliary materials for preparing capsules, such as starch, and mix them, then encapsulate them to make 1000 tablets.

[0017] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example

[0018] Experimental example: Sarcaboside B anti-human fungal activity

[0019] The anti-human fungal activity test is to use the concentration dilution method, and each test is repeated three times. The test pathogens are Trichophyton rubrum, Microsporum laniformis and Trichophyton spp. The concentration of the bacterial solution is 10 5 Pieces / mL. The initial concentration of Sarcaboside B is 50.0μg / mL (5% dimethyl sulfoxide DMSO), and the gradient is diluted to 0.098μg / mL. The same volume of bacteria liquid and test sample are mixed and cultured in a 96-well plate. Human fungal culture temperature Respectively, observe at 28°C for 24 hours of incubation. If no colony formation is found, it is the lowest anti-human fungal concentration of the sample, that is, the MIC value. The positive control of this experiment is ketoconazole, and the results of Sarcaboside B against human fungi are shown in Table 1.

[0020] Table 1 Sarcaboside B anti-human fungus MIC value (μg / mL)

[0021]

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of Lycojaponicumin B in the preparation of medicines for resisting human body fungi, belonging to the field of medicines. The Lycojaponicumin B has very strong inhibitory effect on trichophyton rubrum, microsporum lanosum or trichophyton tonsurans. Therefore, the Lycojaponicumin B can serve as a compound capable of resisting human body fungi and is expected to be applied in the preparation of related medicines. The application of the Lycojaponicumin B in the preparation of the medicines for resisting human body fungi is disclosed for the first time. As the skeleton type of the Lycojaponicumin B belongs to a brand-new skeleton type, the Lycojaponicumin B has unexpected strong inhibitory activity on human body fungi, and the possibility that other compounds provide revelation does not exist. The Lycojaponicumin B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for preventing and treating human body fungi infection.

Description

Technical field [0001] The present invention relates to the use of Sarcaboside B, in particular to the use of Sarcaboside B in the preparation of antifungal drugs. Background technique [0002] The spread of pathogenic bacteria and the enhancement of their drug resistance are a serious threat to human health and life. Antibacterial drugs have been widely used as routine drugs for AIDS, organ transplantation and chronic wasting diseases (such as cancer, diabetes, uremia, etc.) Treatment, although the current clinical use of antibacterial agents (such as ketoconazole, amikacin, gentamicin, viviconazole, itraconazole, terbinafine, amphotericin, fluconazole, etc.) It has a good effect on skin and superficial infections, but these antibacterial drugs have strong accumulated toxicity and often cause liver and kidney damage, digestive tract irritation, dizziness, allergies, etc., so the search for new antibacterial drugs with unique mechanisms of action has become today's drug research ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P31/10
Inventor 江春平陈卫波
Owner NANJING GUANGKANGXIE BIOLOGICAL MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap